Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA

Subcutaneous Aspart Insulin and Point of Care Beta Hydroxybutyrate Testing: A New Paradigm for the Management of Diabetic Ketoacidosis

The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.

Inclusion Criteria: age 18 or older

• venous pH < 7.3 or arterial < 7.35

• at least 2 of the following 3:

  1. serum HCO3 < 18/anion gap > 16
  2. serum glucose > 300 mg/dl
  3. serum acetone positive

Exclusion Criteria:

• pregnant
• less than age 18